Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical progress for its lead candidate HyBryte™, which achieved a 75% response rate in a trial for cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer. The trial is supported by funding from a U.S. Food and Drug Administration’s Orphan Products Development Grant and showcases HyBryte’s™ potential as a first-in-class, light-activated, non-invasive therapy.
HyBryte™ is a first-in-class photodynamic therapy activated by safe visible light and has previously received Orphan Drug and Fast Track designations. Soligenix plans to continue advancing regulatory discussions as it positions HyBryte™ for potential commercialization.
To view the video, visit https://ibn.fm/zT9L1
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (“SGX301” or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
For more information, visit the company’s website at https://www.soligenix.com
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]
MissionIR is powered by IBN
